IBOV 168,481.49 ▲ 1.38% IPC MEX 71,087.56 ▲ 0.38% MERVAL 2,848,945 — — USD/BRL5.50▼ 0.04% USD/MXN18.63▼ 0.68% USD/CLP977.00▼ 0.16% USD/COP3,235▲ 0.24% USD/PEN3.42▼ 0.64% USD/ARS 1,545 — 0.00% USD/UYU40.31▲ 3.48% USD/PYG6,358▲ 8.23% USD/BOB11.81▲ 0.40% USD/DOP60.59▲ 0.48% USD/CRC448.27▲ 1.89% USD/GTQ7.64▲ 3.24% USD/HNL26.88▲ 3.25% USD/NIO36.62▲ 2.77% USD/VES893.88▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.99▲ 2.90% USD/TTD6.72▲ 2.39% EUR/BRL6.13▲ 0.05% BRENT 98.05 ▼ 0.24% WTI 90.45 ▼ 0.08% IRON ORE 161.91 — — COPPER 6.27 ▲ 0.29% GOLD 4,085 ▼ 0.70% SILVER 52.18 ▼ 0.11% SOY 1,192 ▲ 0.93% CORN 442.00 ▲ 0.45% WHEAT 593.75 ▼ 0.92% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 139.15 ▲ 8.33% COTTON 78.54 ▼ 0.22% COCOA 5,239 ▲ 1.12% BEEF 214.05 ▼ 0.16% CATTLE 318.20 ▼ 2.11% LITHIUM 61.01 ▲ 1.37% PETR4 45.10 ▼ 1.85% VALE3 63.86 ▲ 1.90% ITUB4 40.74 ▲ 1.93% BBDC4 14.16 ▲ 2.83% ABEV3 15.55 ▲ 0.45% BBAS3 17.10 ▲ 3.70% B3SA3 14.40 ▲ 0.28% WEGE3 48.12 ▼ 0.37% PRIO3 60.60 ▼ 1.53% SUZB3 52.90 ▲ 1.17% RENT3 30.19 ▲ 3.85% AZZA3 15.02 ▲ 6.83% CSAN3 2.75 ▲ 10.00% RAIZ4 27.30 ▼ 0.98% PCAR3 2.40 ▲ 0.42% GMAT3 3.88 ▲ 4.58% PSSA3 44.31 ▲ 1.37% CVCB3 0.84 ▲ 2.44% POSI3 3.10 ▼ 0.32% SLCE3 16.57 ▲ 1.35% NATU3 5.33 ▼ 0.37% BRKM5 3.19 ▲ 5.28% RANI3 8.45 ▼ 0.12% CSNA3 4.45 ▲ 9.88% IBOV 168,481.49 ▲ 1.38% IPC MEX 71,087.56 ▲ 0.38% MERVAL 2,848,945 — — USD/BRL 5.50 ▼ 0.03% USD/MXN 18.62 ▼ 0.70% USD/CLP 977.85 ▼ 0.08% USD/COP 3,235 ▲ 0.24% USD/PEN 3.42 ▼ 0.64% USD/ARS 1,545 — 0.00% USD/UYU 40.31 ▲ 3.48% USD/PYG 6,358 ▲ 8.23% USD/BOB 11.81 ▲ 0.40% USD/DOP 60.59 ▲ 0.48% USD/CRC 448.27 ▲ 1.89% USD/GTQ 7.64 ▲ 3.24% USD/HNL 26.88 ▲ 3.25% USD/NIO 36.62 ▲ 2.77% USD/VES 893.88 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.99 ▲ 2.90% USD/TTD 6.72 ▲ 2.39% EUR/BRL 6.13 ▲ 0.05% BRENT 98.05 ▼ 0.24% WTI 90.45 ▼ 0.08% IRON ORE 161.91 — — COPPER 6.27 ▲ 0.29% GOLD 4,085 ▼ 0.70% SILVER 52.18 ▼ 0.11% SOY 1,192 ▲ 0.93% CORN 442.00 ▲ 0.45% WHEAT 593.75 ▼ 0.92% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 139.15 ▲ 8.33% COTTON 78.54 ▼ 0.22% COCOA 5,239 ▲ 1.12% BEEF 214.05 ▼ 0.16% CATTLE 318.20 ▼ 2.11% LITHIUM 61.01 ▲ 1.37% PETR4 45.10 ▼ 1.85% VALE3 63.86 ▲ 1.90% ITUB4 40.74 ▲ 1.93% BBDC4 14.16 ▲ 2.83% ABEV3 15.55 ▲ 0.45% BBAS3 17.10 ▲ 3.70% B3SA3 14.40 ▲ 0.28% WEGE3 48.12 ▼ 0.37% PRIO3 60.60 ▼ 1.53% SUZB3 52.90 ▲ 1.17% RENT3 30.19 ▲ 3.85% AZZA3 15.02 ▲ 6.83% CSAN3 2.75 ▲ 10.00% RAIZ4 27.30 ▼ 0.98% PCAR3 2.40 ▲ 0.42% GMAT3 3.88 ▲ 4.58% PSSA3 44.31 ▲ 1.37% CVCB3 0.84 ▲ 2.44% POSI3 3.10 ▼ 0.32% SLCE3 16.57 ▲ 1.35% NATU3 5.33 ▼ 0.37% BRKM5 3.19 ▲ 5.28% RANI3 8.45 ▼ 0.12% CSNA3 4.45 ▲ 9.88%
since 2009
Friday, November 6, 2026

Covid-19 Brazil

Two doses of Pfizer and AstraZeneca vaccines ensure efficacy against Delta variant – study

By · July 21, 2021 · 2 min read

RIO DE JANEIRO, BRAZIL – Two doses of Pfizer and AstraZeneca’s Covid-19 vaccines are nearly as effective against the highly transmissible Delta variant of the coronavirus as against the previously dominant Alpha variant in several countries around the world, a study published Wednesday showed.

Officials say the vaccines are highly effective against the Delta variant, now the dominant strain in most of the world, although the study reiterated that one dose of the vaccines alone is not enough for high protection.

Two doses apparently enough.
Two doses apparently enough.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The study, published in the New England Journal of Medicine, confirms key findings provided by the British government in May on the effectiveness of Covid-19 vaccines made by Pfizer-BioNTech and Oxford-AstraZeneca, based on real-world data.

The study released on Wednesday pointed out that two doses of Pfizer’s vaccine resulted in 88% efficacy in preventing symptomatic disease of the Delta variant, compared to 93.7% against the Alpha variant, in line with what was previously reported.

Two doses of AstraZeneca’s vaccine resulted in 67% efficacy against the Delta variant, up from 60% originally reported, ante 74.5% against the Alpha variant, compared to an original estimate of 66% efficacy.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Paraguay's president tried to quit. Congress said no”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

“Only modest differences in vaccine efficacy were observed with the Delta variant compared with the Alpha variant after receiving two doses of the vaccine,” researchers from the Department of Public Health England wrote in the study.

Data from Israel estimated lower efficacy of Pfizer’s vaccine against symptomatic illness caused by Delta, although protection against the severe disease remains high.

The study published Wednesday found that one dose of Pfizer’s injection was 36 percent effective, and one dose of AstraZeneca’s vaccine was about 30 percent effective.

“Our finding of reduced efficacy after the first dose supports efforts to maximize two-dose vaccine delivery among vulnerable groups in the context of Delta variant circulation,” the study authors said.

Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.